Sök

Esmya användning, rekommendationer från EMA’s Pharmacovigilance Risk Assessment Committee (PRAC)

The PRAC has concluded that Esmya may have contributed to the development of some cases of serious liver injury.* The Committee has therefore made the following recommendations to minimise this risk:

  • Esmya must not be used in women with known liver problems.
  • A liver function test should be performed before starting each treatment course and treatment must not be started if liver enzyme levels are more than 2 times the upper limit of normal.
  • Liver function tests should be performed once a month during the first two treatment courses and two to four weeks after stopping treatment. If the test is abnormal (liver enzyme levels more than 3 times the upper limit of normal), the doctor should stop treatment and closely monitor the patient.
  • Esmya should be used for more than one treatment course only in women who are not eligible for surgery. Women who are about to have surgery should continue to use only one course.
  • A card will be included in the box of the medicine to inform patients about the need for liver monitoring, and to contact their doctor should they develop symptoms of liver injury (such as tiredness, yellowing of the skin, darkening of the urine, nausea and vomiting).
  • Studies should be performed to determine the effects of Esmya on the liver and whether these measures are effectively minimising the risks.

Link to original information